LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

In another Chinese newco out-licensing deal, Innocare Pharma Ltd. and Keymed Biosciences Co. Ltd. out-licensed their co-developed CD20×CD3 bispecific antibody (ICP-B02/CM355) to startup Prolium ...

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...